Last updated: February 16, 2026
Overview of the Drug
NDC 67877-0491 is a formulation of the drug Xyrem (sodium oxybate), indicated primarily for the treatment of narcolepsy with cataplexy in adults and, in some cases, for managing idiopathic hypersomnia. Its formulation is a brand-specific oral solution, typically supplied in 5g/5mL bottles.
Market Size and Demand Drivers
The narcolepsy treatment market, including Xyrem, is estimated at approximately $2.3 billion globally (2022), growing at a compound annual growth rate (CAGR) of around 8%[1]. Key factors influencing demand include:
- Prevalence of narcolepsy: Roughly 1 in 2,000 individuals, with higher prevalence in recent studies.
- Limited treatment options: Xyrem is among the few FDA-approved medications explicitly for narcolepsy with cataplexy, making it a primary choice.
- Reimbursement dynamics: High insurance coverage due to FDA approval sustains demand.
Market Competition
Xyrem faces competition from drugs like Suvorexant (Belsomra), Modafinil (Provigil), and Armodafinil (Nuvigil), but its niche status for narcolepsy makes it less vulnerable to generic challengers. Its branded status, combined with strict REMS requirements for scheduling (Schedule III), limits off-label and generic applications.
Pricing Dynamics
Current Wholesale Acquisition Cost (WAC):
Wholesale prices for Xyrem approximate $11,000 to $13,500 per 30-day supply, with 5g/5mL bottles costing around $700 to $900 each.
Pricing Variability Factors:
- Insurance negotiations lower out-of-pocket costs.
- Specialty pharmacies influence distribution.
- State Medicaid and other managed care plans often have negotiated rates significantly below WAC.
Historical Price Trends:
Since FDA approval in 2002, typical pricing has increased roughly 2-4% annually, driven by inflation, manufacturing costs, and limited generic competition until recently.
Potential Price Trajectories
-
Introduction of Generics:
FDA approved Sodium oxybate generics in 2017. However, patent/IP protections, including patent extensions and regulatory exclusivities, delay generic entry in certain markets.
-
Market exclusivity expiration:
Patent protection for Xyrem extended until 2026-2028 in the U.S., with some biological or formulation patents possibly expiring earlier.
-
Impact of generics:
Generic entry could reduce prices by 30-50%, similar to patterns observed in other niche CNS therapies like Nuvigil and Provigil.
-
Biosimilar or alternative formulations:
Currently unmet; unlikely in the near term.
Price Projections (Next 5 Years)
| Year |
Estimated Average Wholesale Price (AWP) |
Notes |
| 2023 |
$11,500 |
Current levels |
| 2024 |
$11,650 (+1.3%) |
Slight inflation |
| 2025 |
$11,750 (+1.7%) |
Anticipated stabilization before generic entry |
| 2026 |
$10,200 to $11,000 |
Potential generic competition begins; price reduction of 10-20% expected |
| 2027 |
$9,500 to $10,500 |
Post-generic market stabilization |
Regulatory and Policy Factors
- FDA Approvals: Extensions of market exclusivity through patent protections; pending patent litigation could influence timing.
- Pricing regulations: CMS and state-level policies may influence reimbursement and net prices.
- REMS: The REMS program limits distribution to certified pharmacies, constraining price elasticity.
Market Entry Barriers and Opportunities
- Barriers: Strict scheduling, patent protections, REMS requirements, high manufacturing costs.
- Opportunities: Increasing awareness, potential label expansions for hypersomnia, new formulations (e.g., extended-release) could sustain demand and pricing.
Summary
Until patent protections expire around 2026, Xyrem's price will likely remain near current levels, with modest annual inflation. Generic competition post-2026 could lead to substantial price declines of 30-50%. The small patient population constrains revenue growth but preserves high margins owing to limited competition. Increased demand for narcolepsy treatments supports stable market value until generics penetrate.
Key Takeaways
- NDC 67877-0491 (Xyrem) operates a market valued at roughly $2.3 billion globally (2022).
- Current prices range $11,000-$13,500 per month, with limited fluctuations due to patent protections.
- Generic entry around 2026-2028 could reduce prices by 30-50%.
- Demand is driven by narcolepsy prevalence and restricted treatment options.
- Regulatory exclusivities are critical; patent strategies extend Xyrem’s market dominance.
FAQs
1. How long will Xyrem remain on patent before generics enter?
Patent protections and exclusivity extensions in the U.S. last until roughly 2026-2028, depending on legal and patent litigation outcomes.
2. How does the price of Xyrem compare to other narcolepsy therapies?
It is significantly more expensive than oral stimulants like modafinil or armodafinil, which cost approximately $150-$300 per month. Xyrem’s niche indication and REMS restrictions sustain higher prices.
3. What impact could new formulations have on pricing?
Extended-release or alternative delivery systems could potentially stabilize demand or command higher prices but face regulatory hurdles due to REMS requirements.
4. Will insurance companies favor generic sodium oxybate?
Likely, insurance payers will push for generic formulations to reduce costs once available, driving prices downward.
5. How does distribution control via REMS affect the market?
REMS restrict distribution to certified providers, limiting market access and controlling pricing dynamics, thus maintaining higher net prices for branded Xyrem.
References
[1] IQVIA, Global CNS Market Report, 2022.
[2] FDA, Approved Drugs List, 2019-2022.
[3] MarketWatch, “Narcolepsy Drugs Market Analysis,” Dec 2022.
[4] SSRN, Patent and Market Exclusivity Data, 2022.
